Our CEO, Beth Hoffman, shares some of her insights into how to approach novel CNS targets by targeting the root cause in order to to slow or halt disease progression on pg. 24 of the latest issue of California Life Sciences digital magazine, Life Sciences Insights....

Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in...

The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to...

Protein degradation is an up-and-coming approach that most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. Read full article

Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and...

Listen to the Podcast

Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...

28 Feb – 3 March, 2022 Presenting at 17th Annual Huntington’s Disease Therapeutics Conference https://web.cvent.com/event/a0991146-7ae2-4f10-bc6c-0bf856caac34/summary   28-30 March, 2022 Presenting at 10th Annual Neurodegenerative Drug Development Summit...

Targeted protein degradation (TPD) is emerging to be a promising technology for targeting disease-causing proteins. Through the mechanism of hijacking either the ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway the protein of interest is degraded,...

Learn more about Origami, one of Biocenturys 2021 class of emerging companies.

See the BioTech Showcase Agenda

The Huntington’s Disease Society of America (HDSA) is proud to announce that Jeff Carroll, PhD and Beth Hoffman, PhD have been elected to the Society’s National Board of Trustees. Learn More

Learn about the Panelists

Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry. Learn more

View the presentation

Emerging Company Profile – Origami: Correcting or eliminating misfolded proteins. Learn More

Presenting Company event information  

Click to learn more

Presentation: Triaging Your Drug Targets to Find the Most Relevant Lead (CEO Beth Hoffman) https://www.hub-xchange.com/cns-therapeutics-xchange-west-coast-2021/#anchor1

The Tau Consortium is a collaborative research program that is managed and funded by the Rainwater Charitable Foundation in partnership with other funders. Read More